Lilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual Meeting
StockNews.AI · 3 hours
AI Summary
Lilly disclosed Phase 1 AJX-101 results for AJ1-11095, a first-in-class type II JAK2 inhibitor, in myelofibrosis patients who failed type I inhibitors. The data show 70% SVR35 and 70% TSS50 at week 12, plus substantial VAF reductions and a generally manageable safety profile with no dose-limiting toxicities. The company also highlighted Ajax acquisition integration and an EHA presentation, signaling potential long-term upside but still early-stage risk.
Sentiment Rationale
Positive early data and a completed acquisition expand Lilly's MF/JAK2 portfolio; potential rerating if early signals persist, but still early-stage, limiting near-term upside.
Trading Thesis
Longer-term upside for LLY if AJ1-11095 progresses; near-term upside potential around EHA data.
Market-Moving
- EHA 2026 presentation (Abstract S218) could trigger a near-term stock move depending on data strength.
- Ajax Therapeutics acquisition completed; pipeline expansion may unlock multiple catalysts.
- Early-stage data carry inherent execution risk; review subsequent cohorts and regulatory milestones.
Key Facts
- Lilly reports Phase 1 AJX-101 data for AJ1-11095; early safety and activity.
- SVR35 reached in 70%; TSS50 at week 12 also 70%; VAF reductions in 21/23 patients.
- By week 24, 59% had ≥20% VAF decline; 35% ≥50% decline.
- No dose-limiting toxicities; safety generally manageable; common AEs include anemia, dysgeusia, thrombocytopenia, and elevated ALT.
- Ajax acquisition completed; EHA 2026 abstract S218; expansion in second-line MF.
Companies Mentioned
- Eli Lilly and Company (LLY): Announced AJX-101 Phase 1 results; AJ1-11095 integrated into Lilly's pipeline with potential upside if later-stage data prove durable.
- Ajax Therapeutics (N/A): Acquired by Lilly; AJX-101/AJ1-11095 now part of Lilly's oncology portfolio with potential downstream value.
Industry News
Industry News: This is a pipeline progress update and corporate development tied to Lilly's oncology strategy, with potential long-term upside if the program advances.